What is the clinical evidence from this study?

Study design: Cohort. Population: Diabetic nephropathy (n=64). Intervention: GLP-1RAs vs. Other treatments (ARBs, SGLT2i, or none). Primary outcome: eGFR slope (annual change in eGFR) (Coefficient -6.43, 95% CI -10.17 to -2.70, p=<0.01).

What question did this study set out to answer?

The study aims to identify factors impacting the improvement of eGFR slope in patients with diabetic nephropathy at high risk of progression.

April 17, 2026Open Access

Exploration of factors associated with eGFR slope improvement before and after intensive treatment of patients with diabetic nephropathy at high risk of disease progression: a retrospective cohort study

Q: What are the key findings of this study?

Treatment with GLP-1RAs was significantly associated with an improvement in eGFR slope in patients with diabetic nephropathy at high risk of disease progression.

Q: What does this research mean for the field?

Treatment with GLP-1RAs is significantly associated with an improvement in eGFR slope in patients with diabetic nephropathy at high risk of disease progression. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

The study aims to identify factors impacting the improvement of eGFR slope in patients with diabetic nephropathy at high risk of progression.

Key Result

Treatment with GLP-1RAs was significantly associated with an improvement in eGFR slope in patients with diabetic nephropathy at high risk of disease progression.

Key Points

The study aims to identify factors impacting the improvement of eGFR slope in patients with diabetic nephropathy at high risk of progression.
Retrospective cohort study design
Analyzed data from patients with eGFR < 30 mL/min/1.73 m2
Examined annual changes in eGFR slope before and after intensive treatment
Identified various factors associated with eGFR improvement
Significant positive changes in eGFR slope observed post-treatment
Certain factors correlated with better eGFR improvement
Overall progression risk for diabetic nephropathy patients reduced by targeted interventions

Study Design

Type

Cohort (n=64)

Multicenter

Structured PICO

هل العلاج المكثف يحسن ميل معدل الترشيح الكبيبي التقديري (eGFR) في مرضى الكلى السكري الذين هم في خطر كبير لتقدم المرض؟

Population

مرضى الكلى السكري الذين هم في خطر كبير لتقدم المرض، لا سيما أولئك الذين لديهم eGFR أقل من 30 مل/دقيقة/1.73 م²

Intervention

علاج مكثف

Comparator

خط الأساس قبل العلاج (قبل العلاج المكثف)

Outcome

تحسين في التغير السنوي في معدل الترشيح الكبيبي التقديري (ميل eGFR)surrogate

Main Result

Effect estimate: Coefficient -6.43 (95% CI -10.17 to -2.70)

p-value: p=<0.01

Limitations

Retrospective design
Small sample size
Lack of distinction between monotherapy and combination therapy
Could not adequately account for medication duration or dosage
Advanced nephropathy limits generalizability

Abstract

Objective: To explore the factors that contribute to the improvement in the annual change in the estimated glomerular filtration rate (eGFR slope) in patients with diabetic nephropathy at high risk of disease progression, particularly those with an eGFR of less than 30 mL/min/1.73 m2.

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

أجرى كيكو وآخرون (الخميس) دراسة ميدانية في مرضى الكلى السكري (عدد = 64). تم تقييم GLP-1RAs مقابل علاجات أخرى (ARBs، SGLT2i، أو عدم وجود) على ميل eGFR (التغير السنوي في eGFR) (معامل -6.43، 95% CI -10.17 إلى -2.70، p=<0.01). كان العلاج بـ GLP-1RAs مرتبطًا بشكل كبير بتحسين ميل eGFR في مرضى الكلى السكري المعرضين لمخاطر عالية لتقدم المرض.

synapsesocial.com/papers/69e1cdc45cdc762e9d857155 https://doi.org/https://doi.org/10.2185/jrm.2025-039